Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Myriad Genetics (MYGN) Short term Debt (2016 - 2025)

Historic Short term Debt for Myriad Genetics (MYGN) over the last 7 years, with Q2 2025 value amounting to $59.4 million.

Myriad Genetics' Short term Debt changed N/A to $59.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $59.4 million, marking a year-over-year change of. This contributed to the annual value of $3.1 million for FY2020, which is 882.35% down from last year.
According to the latest figures from Q2 2025, Myriad Genetics' Short term Debt is $59.4 million.
Myriad Genetics' 5-year Short term Debt high stood at $104.1 million for Q2 2021, and its period low was $59.4 million during Q2 2025.